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The class II MHC protein HLA-DR1 in complex with an endogenous
peptide: implications for the structural basis of the specificity of
peptide binding
Venkatesh L Murthy1 and Lawrence J Stern2*
Background: Class II major histocompatibility complex (MHC) proteins are cell
surface glycoproteins that bind peptides and present them to T cells as part of
the mechanism for detecting and responding to foreign material in the body.
The peptide-binding activity exhibits allele-specific preferences for particular
sidechains at some positions, although the structural basis of these preferences
is not understood in detail. We have determined the 2.45 Å crystal structure of
the human class II MHC protein HLA-DR1 in complex with the tight binding
endogenous peptide A2(103–117) in order to discover peptide–MHC
interactions that are important in determining the binding motif and to
investigate conformational constraints on the bound peptide.
Results: The bound peptide adopts a polyproline II-like conformation and
places several sidechains within pockets in the binding site. Bound water
molecules mediate MHC–peptide contacts at several sites. A tryptophan
residue from the β2 ‘lower’ domain of HLA-DR1 was found to project into a
pocket underneath the peptide-binding domain and may be important in
modulating interdomain interactions in MHC proteins. 
Conclusions:  The peptide-binding motif of HLA-DR1 includes an aromatic
residue at position +1, an arginine residue at position +2, and a small residue
at position +6 (where the numbering refers to the normal MHC class II
convention); these preferences can be understood in light of interactions
observed in the peptide–MHC complex. Comparison of the structure with
that of another MHC–peptide complex shows that completely different
peptide sequences bind in essentially the same conformation and are
accommodated with only minimal rearrangement of HLA-DR1 residues. Small
conformational differences that are observed appear to be important in
interactions with other proteins. 
Introduction
Class II major histocompatibility complex (MHC) glyco-
proteins are found on the surface of B cells, macrophages,
dendritic cells, and other specialized immune system cells.
They bind peptides within endosomal compartments and
present them at the cell surface for interaction with T-cell
receptors as part of the immune system’s mechanism for
detecting and responding to foreign material in the body
[1]. The interaction of peptide–MHC protein complexes
with antigen receptors on the surface of T cells causes T-
cell activation and stimulation of an immune response. In
order to help stimulate immune responses against a wide
variety of possible pathogens, MHC proteins can bind
tightly to many different peptides. Class II MHC proteins
isolated from B cells carry a wide spectrum of endogenous
and exogenous peptides [2–4]. Analysis of these peptide
mixtures and of the peptide-binding preferences of iso-
lated class II MHC proteins has identified peptide-
binding ‘motifs’, or patterns of preferred residues at
different peptide positions [5,6]. Peptide-binding motifs
proposed for class II MHC proteins generally include
residue preferences at positions 1, 4, 6 and 9, where posi-
tion 1 is at an arbitrary point near the peptide N terminus,
and where the particular residues preferred at these posi-
tions vary for different MHC allelic variants [7]. 
Structural characterization of class II MHC proteins bound
to mixtures of endogenous peptides [8,9], or to single,
defined peptides [10–12], has identified a general mode of
peptide binding. Subsites or ‘pockets’ within the peptide-
binding groove accommodate some of the bound peptide’s
sidechains. The residues lining the pockets appear to be
responsible for the different motifs, or peptide-binding
preferences of different allelic variants. The peptide
termini do not play a major role in the binding mechanism,
and can extend out from the site. This mechanism contrasts
with that observed for class I MHC proteins, where pep-
tides of sharply defined length bind through interactions
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between the peptide termini and pockets at the ends of the
peptide-binding site [13,14]. Although the basic mode of
peptide interaction with class II MHC has been identified
and subsites important to the peptide-binding specificity
have been located, several important aspects of the
peptide-binding interaction are not understood. These
aspects include the extent of conformational variability
allowed in the peptide-binding site, the role of solvent mol-
ecules in the binding interaction, and the structural basis for
the observed peptide-binding motif. 
Here we describe the crystal structure of HLA-DR1, a
human class II MHC protein, in complex with a 15-
residue endogenous peptide, and use the structure to help
clarify these issues. The peptide A2(103–117) derives
from the class I MHC protein HLA-A2 and is the predom-
inant endogenous peptide bound to HLA-DR1 isolated
from a B lymphoid cell line [2], presumably reflecting the
abundance of the HLA-A2 protein in the endosomal sub-
cellular compartment where peptide binding occurs. The
A2 peptide conforms to the peptide-binding motif identi-
fied for HLA-DR1, and places the sidechains of ‘anchor’
residues tryptophan, leucine, and glutamine into MHC
pockets 1, 4 and 9, respectively, and a glycine residue into
pocket 6. Interactions observed in the crystal structure at
the ‘minor’ anchor positions 2, 3 and 7 help to explain fea-
tures of the peptide-binding preferences observed for
HLA-DR1. Several water molecules are observed to
mediate interactions between MHC residues and the
bound peptide. Comparison of the structure of the HLA-
DR1–A2 peptide complex with that previously deter-
mined for the HLA-DR1 complex with HA(306–318) [10],
a peptide of completely different sequence, allows us to
explore the plasticity of the peptide-binding site and 
the extent of conformational variation in the presence of
different ligands. We also describe interactions among the
peptide-binding and the immunoglobulin (Ig)-like
domains, and explore the implications of the observed
peptide conformational variability for T-cell activation.
Results and discussion
Structure determination
The structure of the complex of HLA-DR1 with A2(103–
117) peptide was determined using diffraction data col-
lected with synchrotron radiation and a single crystal
cooled to –175°C (see Materials and methods section for
details of data collection and refinement). Initial phase
estimates were obtained by molecular replacement using
the 2.75 Å model of the HLA-DR1–HA(306–318) peptide
complex [10] with all peptide atoms omitted as the search
model. Unambiguous electron density was observed for
the bound peptide (Figure 1a). The initial electron-density
maps were improved by iterative averaging of the noncrys-
tallographically-related domains, and by cycles of manual
model building and automated refinement (Figure 1b).
The asymmetric unit contains four αβ complexes, arranged
as two copies of essentially the same (αβ)2 dimer observed
in other HLA-DR1 crystal structures [8–11,15,16]. Root
mean square (rms) deviations between pairs of noncrystal-
lographically-related domains range from 0.13 to 0.15 Å
(see Materials and methods section). In keeping with the
class II convention, we will refer to the peptide sidechain
that projects into the large hydrophobic pocket near the N
terminus as position +1, so the A2(103–117) peptide corre-
sponds to positions –4 to +11. 
Conformation of the bound peptide
The A2 peptide is bound in the peptide-binding site of
HLA-DR1 in an extended, polyproline type II-like confor-
mation (Figure 2a) as observed for other class II
MHC–peptide complexes [10–12]. Both peptide termini
extend from the site and are partially disordered. The core
region of the peptide (positions –2 to +10) is well ordered
and makes many contacts with HLA-DR1 (Table 1). The
interaction between HLA-DR1 and the bound peptide
covers just over half of the peptide surface, and buries
1750 Å2 of molecular surface area [17]. The bound peptide
is contacted by 36 MHC residues, with mostly polar atoms
contacting the peptide mainchain, and mostly hydrophobic
atoms contacting the sidechains in the principal sidechain-
binding pockets 1, 4 and 9. At Ser(–2) the peptide kinks
sharply (Figures 2a,b), orienting N-terminal residues
Gly(–3) and Val(–4) towards the DR1β chain and breaking
the polyproline repeat. In other class II MHC-peptide
structures [10–12], electron density N-terminal to position
–2 is weak but consistent with peptides extending straight
out of the peptide-binding site. In the A2 peptide the
kinked residues have little contact with MHC atoms
(Table 1), and the kinked orientation may be specific to
this peptide as it appears to be due to a set of electrostatic
interactions linking the Gly(–3) mainchain, Asp(–1) car-
boxylate, and Arg(+2) guandinium groups. 
The bound A2 peptide makes many interactions with
HLA-DR1 through its mainchain atoms, and forms 14
hydrogen bonds directly with HLA-DR1 atoms
(Figure 2b; yellow). Similar patterns of hydrogen bonding
have been observed in other class II MHC structures
[8–12] and proposed to play a general role in the tight
binding of peptides; in particular, the asparagine and
glutamine bidentate hydrogen bonds help to determine
the polyproline conformation [8]. In addition to the direct
HLA-DR1–peptide hydrogen bonds, several buried water
molecules mediate hydrogen-bonding interactions
between HLA-DR1 and the bound A2 peptide
(Figure 2b; pink). Four of these water molecules are
found as part of an elaborate hydrogen-bonding network
underneath the central portion of the peptide (see
below). A similar network has been observed in the
murine class II MHC protein I-Ek and proposed to play a
role in the pH dependence of peptide binding [12].
Three additional water molecules form hydrogen bonds
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to exposed peptide mainchain atoms oriented away from
the peptide-binding site (Figure 2b; blue).
Pockets in the peptide-binding site and the specificity of
peptide binding
Interactions between sidechains from the bound peptide
and pockets in the peptide-binding site are important in
determining the peptide-binding affinity and sequence
specificity of MHC proteins. The sidechains of the A2
peptide residues Trp(+1), Leu(+4) and Gln(+9) are buried
in pockets in the binding site, with the sidechains of
Arg(+2), Phe(+3) and Tyr(+7) also making substantial con-
tacts in shallow pockets or ‘shelves’ within the overall
peptide-binding site (Figure 2c; Table 1). 
Pocket 1 is the largest [10] and most important [6,18,19] of
the sidechain-binding pockets in HLA-DR1. The A2
peptide places tryptophan, one of the preferred ‘anchor’
residues at this position [6], into pocket 1. Unexpectedly,
the tryptophan sidechain is oriented differently than the
tyrosine found at this position in the HA peptide complex
(Figure 3a). The new orientation corresponds to an approx-
imately 80° rotation around the Cα–Cβ bond. In the new
orientation, the tryptophan ring plane is perpendicular to
Pheα24 (where α refers to the α subunit of HLA-DR1),
with the indole nitrogen centered over the Pheα24 aro-
matic ring, apparently interacting with its pi-electron cloud.
Similar electrostatic interactions have been observed previ-
ously [20–22]. The sidechain rotation at position Trp(+1)
causes some alteration of the A2 peptide mainchain rela-
tive to that of the HA peptide, especially near the carbonyl
of residue (–1) (Figure 3a). The different sidechains of the
A2 and HA peptides, however, are accommodated with
very little variation in the MHC residues that line pocket 1. 
Pockets 4 and 9 of class II MHC proteins are also major
pockets which bury substantial sidechain solvent-exposed
surface area (Table 1). HLA-DR1 exhibits preferences for
hydrophobic residues at these positions of the peptide, but
hydrophilic residues with large aliphatic portions also are
tolerated [6,18,23]. The A2 peptide places Leu(+4) into
pocket 4, where it is ~90% buried by interactions with
Pheβ13, Alaβ74 and Tyrβ78. The Gln(+9) sidechain of A2
peptide is oriented down into pocket 9, where it contacts a
hydrophobic surface formed by atoms from Asnα69,
Ileα72, Metα73, Trpβ9 and Trpβ61. The terminal amide
of Gln(+9) packs against the salt bridge Argα76–Aspβ57 at
the very bottom of the pocket. In both pockets 4 and 9
similar interactions were observed in the HLA-DR1–HA
peptide complex [10].
Pocket 6 is also an important determinant of peptide
binding, with HLA-DR1 preferring to bind peptides with
small sidechains (glycine or alanine) at this position [6].
The A2 peptide has Gly(+6) at this position, and in the
HLA-DR1–A2 peptide complex a water molecule binds in
pocket 6 (Figure 3b). The water molecule can participate
in hydrogen bonds with the A2 peptide mainchain nitrogen
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Figure 1
Peptide electron density. Maps calculated
with |2Fo–Fc| coefficients and model phases,
contoured at 1σ, with peptide atoms omitted
from the model. A side view of the peptide-
binding site is shown, with the peptide
running horizontally in the center of the figure
with the N terminus on the left. The final
model is superimposed on the map, with
bonds colored according to atom type. Water
molecules above and below the peptide are
shown as spheres. (a) Map calculated with
initial molecular replacement model. (b) Map
calculated with final model.
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Figure 2
Structure of the HLA-DR1–A2 peptide
binding site. (a) Top view of the peptide-
binding site, with HLA-DR1 residues in
contact with the peptide indicated with
sidechain or mainchain atoms as appropriate.
Atoms are colored by atom type, with oxygen
in red, nitrogen in blue and carbon atoms in
green for the peptide and yellow for HLA-
DR1. The peptide residues are numbered,
with Trp(+1) in the principal binding pocket;
hydrogen bonds are shown in magenta. (b)
Schematic diagram of peptide hydrogen-
bonding interactions. The peptide sidechains
are shown as Rn except for arginine at
position 2 which contacts the HLA-DR1
mainchain carbonyl β77 at a kink in the β-
chain helical region. The sidechain of His(+8)
is also positioned to form a hydrogen bond
with HLA-DR1 (not shown). The peptide
mainchain is shaded in green. The interactions
are color-coded: HLA-DR1–peptide hydrogen
bonds, yellow; hydrogen bonds to buried
water molecules, pink; hydrogen bonds to
exposed water molecules, blue; Arg(+2)
guanidinium–HLA-DR1 β77 carbonyl
hydrogen bond, red. (c) Top view of the
peptide-binding site, with the molecular
surface indicated by blue dots. A Cα trace for
HLA-DR1 is shown together with a stick
model for the A2 peptide and buried water
molecules; bonds are colored by atom type
and water molecules are shown as spheres.
Not all water molecules are observed in each
molecule in the asymmetric unit. 
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Structure
at position (+6) and with HLA-DR1 residues Gluα11 and
Aspα66 (Figure 2b). Alanine is another favored residue at
this position and could bind in the pocket without displac-
ing the bound water molecule by packing against Valα65
and Leuβ11. In the HA peptide, Thr(+6) binds into pocket
6 [10], shifting Asnα62, Valα65 and Aspα66 and displacing
the bound water molecule (Figure 3b). Threonine is not a
favored residue at position 6, and substitution of the HA
peptide threonine by alanine increased binding affinity
threefold [18]. This effect was also seen in a minimal,
alanine-based peptide, where threonine to glycine substi-
tution also caused an increase in peptide-binding affinity,
~tenfold [24]. Comparison of the HA and A2 peptide com-
plexes in this region suggests that the threonine sidechain
makes unfavorable polar–nonpolar contacts between its Cγ
atom and polar residues near the water site, and between
its sidechain hydroxyl group and Val α65. These changes
are thought to be responsible for the decreased affinity.
The Arg(+2) sidechain of A2 peptide is not bound in a
pocket (Figures 2b,c), but appears to play an important role
in peptide binding to HLA-DR1. A preference for arginine
at position (+2) was observed in studies of a minimal HLA-
DR1-binding peptide, where the presence of arginine at
this position provided an ~tenfold increase in binding affin-
ity [23]. In the A2 peptide complex Arg(+2) is oriented up
out of the binding site towards the β-chain helix, with one
of its terminal nitrogen atoms hydrogen-bonding to the
mainchain carbonyl oxygen of Thrβ77 (Figures 2a,b).
Residue Thrβ77 is at a pronounced kink in the β-chain
helical region that accompanies a pi helix→α helix transi-
tion (Figure 2a). The change in hydrogen-bonding pattern
at the kink leaves the Thrβ77 carbonyl oxygen without an
interhelical hydrogen bond. The interaction of the Thrβ77
carbonyl with the guanidinium of Arg(+2) appears to stabi-
lize the helical structure by hydrogen-bonding with the free
carbonyl oxygen. Interestingly, in the structure of the
murine class II MHC protein I-Ek–Hb peptide complex, a
threonine residue at position +2 plays a similar role by
hydrogen bonding to the other lone pair of the free carbonyl
oxygen at residue β77  [12]. 
In the structures of other class II MHC–peptide com-
plexes [10,11], the peptide sidechains at positions 3 and
7 were observed to make substantial hydrophobic con-
tacts with ‘open pockets’ or ‘shelves’ in the binding site.
No strong sequence preferences are observed at these
positions. The A2 peptide has Phe(+3) and Tyr(+7), both
oriented upwards but making substantial hydrophobic
contacts as they exit the peptide-binding site (Figure 2;
Table 1). Phe(+3) is partly exposed in the complex
which may mitigate any favorable interactions formed in
the pocket. Tyr(+7) exhibits weak density and is found
in two alternate conformations in different molecules in
the asymmetric unit (Table 1). The β-chain helical
region around pocket 7 is poorly determined and some-
what variable among class II MHC structures [8–12], and
the variability around this pocket may be due to the
influence of crystal contacts and intrinsic flexibility in
this region of the protein. 
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Table 1
Peptide–MHC interactions.
Residue Position Buried area (Å2)* Mainchain contacts† Sidechain contacts†
Val‡ –4 – – – 
Gly –3 14 (0.21) (β81H) (β85V) –
Ser –2 62 (0.52) α52 α53S β85V α51 (α52 α53S)
Asp –1 28 (0.35) α53S β81 β85V β81H
Trp +1 230 (0.97) α53 α54F β82N α7I α24F α31I α32F α52A α53 β82N β85V β86
Arg +2 95 (0.52) α24F β78Y β82N β77 β81H β82N
Phe +3 93 (0.63) α9Q β78Y α9Q α22F α24F α54F α58 α62N
Leu +4 154 (0.89) α9Q α13Y α62N β78Y β13F β74A β78Y
Arg +5 94 (0.50) α62N β13F β71R α58 α61A α62N α65V
Gly +6 54 (0.87) α65V β11L –
Tyr§ +7 160 (0.76) α65V α69N β61W β67L (β47Y β70Q β71R)§ (β60Y β61W β64Q)§
His +8 73 (0.42) α69N β60Y β61W α65V α68A α69N
Gln +9 160 (0.96) α69D α72I β61W β57D α69N α72I α73M α76R β9W β57D β61W
Tyr +10 106 (0.49) α72I α76R β60Y β57D α76R β56P β57D β60Y
Ala# +11 0 – –
*The solvent-accessible surface [55] in the free peptide that is
sequestered upon formation of the MHC–peptide complex. Values are
the average for four molecules in the asymmetric unit. The buried
fraction (ratio of the buried area to the total solvent-accessible surface
area for the residue in the free peptide) is shown in parentheses.
Corresponding values for the molecular surface [17] follow the same
trend and range from 0 Å2 for Ala(+11) to 143 Å2 (0.92) for Trp(+1).
†MHC residues with atoms closer than 4 Å to peptide mainchain or
sidechains are listed. Residues listed without amino acid names make
contact through their mainchain only. Contacts that differ for the two
orientations are indicated in parentheses. ‡Val(–4) is disordered and
coordinates were not included in the model. Weak electron density at
this position indicates minimal contact with HLA-DR1. §The sidechain
of Tyr(+7) is found in two different orientations in different monomers
in the asymmetric unit. #Ala(+11) makes no substantial contact with
HLA-DR1.
Buried water molecules
Three buried water molecules are found underneath the
peptide in the region between pockets 6 and 7. One water
molecule participates in hydrogen bonds with the A2
peptide amide nitrogen at position 7 and with Cysβ30
from the floor of the peptide-binding site (Figures 2b,c).
This water molecule is also present in the HLA-DR1–HA
peptide complex [10]. In many other class II alleles, tyro-
sine or histidine is found at position β30. These larger
sidechains can displace the water molecule, and directly
form a hydrogen bond with the peptide amide nitrogen, as
observed in the structures of the homologous human
HLA-DR3 [11] and murine I-Ek [12] class II MHC pro-
teins. Binding sites for two other water molecules can be
observed in this region, below the peptide between
pockets 6 and 7 (Figures 2b,c). Water molecules in these
sites can hydrogen bond with HLA-DR1 residues and
with the water molecule described above bound to the
peptide amide at position 7. This network of water mol-
ecules is variously occupied in the four molecules in the
asymmetric unit, and has not been observed previously in
lower resolution HLA-DR structures, although similar
water molecules were observed in a murine I-Ek peptide
complex [12]. The buried water molecules may help to
accommodate conformational variability between differ-
ent peptides, and this region of the binding site exhibits
the largest variability in peptide conformation among class
II MHC peptide complexes determined to date [10–12];
the average mainchain deviation is ~1 Å for positions (+5)
to (+8), compared with ~0.5 Å for positions (–1) to (+4). A
similar role for bound water molecules in accommodating
peptide conformational variability has been postulated in
class I MHC proteins [25].
Potential sites for additional water molecules are also
observed in the vicinity of pocket 1. In the structure of the
HLA-DR1–HA peptide complex, two water molecules were
observed in the bottom of pocket 1, apparently forming
hydrogen bonds to Thrβ90 and the peptide’s tyrosine
hydroxyl group [10]. In the HLA-DR1–A2 peptide
complex, the tryptophan sidechain of the bound peptide
cannot provide a hydrogen bond to a water molecule bound
to Thrβ90, and no ordered water molecules can be detected
in this region. However, a void that could accommodate one
to two water molecules is found adjacent to pocket 1 in all of
the molecules in the asymmetric unit, and disordered
solvent is likely to be present. Two water molecules occupy
another site between pockets 1 and 4 in the HLA–DR1–A2
peptide complex (Figure 3c); these water molecules were
not observed in the HLA-DR1–HA peptide complex. No
naturally occurring peptide sidechain could displace any of
the waters in this region without substantial peptide confor-
mation rearrangement, and these additional water molecules
may not be important for peptide sidechain selectivity.
Adjustment of the HLA-DR1 peptide-binding site to
different peptides
Comparison of the structure of the HLA-DR1–A2 peptide
complex with that observed for the HA peptide complex,
shows that the peptides bind with similar conformation
and in the same register (i.e. placing sidechains at positions
1, 4, 6 and 9 in pockets in the binding site; Figure 4a). The
conformation of the HLA-DR1 protein mainchain is also
essentially unchanged between the A2 and HA peptide
complexes (Figure 4b). The largest mainchain deviations
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Figure 3
Pockets in the peptide-binding site. (a) Side view of pocket 1 in the A2
(green) and HA (purple) peptide complexes. The A2 peptide places a
tryptophan sidechain into pocket 1, and the HA peptide places a
tyrosine sidechain into this pocket. (b) Top view of pocket 4, colored
as in (a). The A2 peptide has a glycine at position 4 and a water
molecule (cyan) binds in the pocket in place of the sidechain; the HA
peptide places a threonine sidechain into pocket 4 without bound
water molecules. Hydrogen bonds are shown as dotted lines.
(~1.0–1.5 Å) occur at a kink in the β-chain helical region
(β65–70) near pocket 7, a region that exhibits high B
factors in all class II MHC structures and may be some-
what flexible. Smaller mainchain deviations (~1 Å) at the
N-terminal end of the peptide-binding region (α50–51,
β85–86) are consistent with slight rearrangements around
pocket 1. Overall, the rms deviation between mainchain
atoms in the binding domains of the A2 and HA peptide
complexes is 0.45 Å, and standard deviations of corre-
sponding phi and psi angles are 7° and 12°, respectively.
All of these deviations are within the range observed
between the four identical molecules in the HLA-DR1–A2
asymmetric unit. The pattern of hydrogen bonds between
HLA-DR1 and the peptide mainchain atoms (Figure 2b) is
also similar between the two complexes. There are only
three differences in the hydrogen-bonding pattern within
the A2 complex: the A2 peptide N-terminal kink prevents
one hydrogen bond between the peptide (–2) amide nitro-
gen and HLA-DR1 residue α51; the Glnα9 terminal amide
forms two hydrogen bonds with the peptide (+4) amide
rather than one; and a bound water molecule substitutes
for one of the Asnα62 hydrogen bonds by interacting with
the peptide amide nitrogen at position (+6). 
Surprisingly, the different peptide sequences are accom-
modated with essentially no change in the conformation of
the sidechains of MHC residues contacting the peptide
(Figure 4b). The rms deviation for sidechains of residues
that contact the peptide is 0.3 Å and the standard devia-
tions of χ1 and χ2 angles for residues in contact with the
peptide in the two structures are 8° and 10°, respectively.
These values are essentially identical to the values for all
residues in the peptide-binding domain (0.3 Å, 11° and
11°). Significant (> 1Å) sidechain alteration between MHC
residues in the A2 and HA peptide complexes is observed
only at three places: β67, β70 and in pocket 1. The motion
of Glnβ70 (Figure 4b; light green triangle) represents the
largest change of MHC residues in the two structures.
With Gln(+4) of the HA peptide bound in pocket 4,
Glnβ70 at the end of the pocket forms hydrogen bonds
with the exposed amide at the end of the sidechain. With
A2 peptide Leu(+4) bound in pocket 4, Glnβ70 rotates
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Figure 4
Conformational flexibility in the peptide-
binding site. (a) Side-view comparison of A2
(green) and HA (purple) peptides after
alignment of the HLA-DR1 peptide-binding
domains. (b) Comparison of MHC residues
contacting the peptide for the A2 and HA
complexes, top view, with residues contacting
the A2 peptide in green and residues
contacting the HA peptide in purple. Cα
traces for the peptide-binding domains in the
two complexes are shown. The positions of
the sidechain-binding pockets (solid circles)
and shelves (dotted circles) are shown. Light
green triangles indicate the most significant
alteration between HLA-DR1 bound to the HA
or A2 peptide.
away from pocket 4 towards pocket 7, to make a hydrogen
bond with the exposed hydroxyl group of Tyr(+7). Leuβ67
is located at the flexible kink of the β chain noted above,
and shifts slightly between the A2 and HA peptide com-
plexes to interact with the residue in pocket 7. Finally,
several residues in pocket 1 show small reorientations in
accommodating the A2 tryptophan anchor residue or the
HA tyrosine anchor residue (Figures 3a and 4b). No other
significant changes are observed between the two sites. 
Interaction between domains 
In addition to the peptide-binding domain described
above, the class II MHC αβ heterodimer comprises two
Ig-like domains, two transmembrane spans and two small
cytoplasmic portions. Interactions between the different
domains have not been described in detail as they have for
class I MHC proteins [25,26]. These interactions are likely
to be important in determining the patterns of MHC αβ
chain pairing in heterozygotes, where several different α
and/or β chains may be present [27–29], and may be
important in orienting the molecule on the cell surface for
interaction with receptors on other cells. We describe here
the interactions between the extracellular α1β1 peptide-
binding domain and the α2 and β2 Ig-like lower domains
(Figure 5a). The peptide-binding domain contacts the
lower Ig-like domains α2 and β2 at two sites. The larger
contact site is formed by the underside of the β sheet from
the peptide-binding domain (Figure 5; green) packing
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Figure 5
Domain interactions in class II MHC proteins. (a) Side view of the HLA-
DR1 αβ heterodimer with the β subunit at the front and the peptide at
the top. The protein is shown as a ribbon diagram with the α subunit in
white, β subunit in gray, and the A2 peptide in dark gray; residues
involved in domain interactions are indicated as colored sidechains or
Cα atoms. Residues from the peptide-binding domain (α1β1) involved
in interactions with the immunoglobulin-like domains α2 or β2 are
colored green (α8, 10, 12, 14, 17, 21, 23, 26–31, 33, 44, 45, 48, β6,
8, 10, 12, 29, 31, 34); residues from α2 involved in interactions with the
peptide-binding domain are colored red (α113–116, 135–146, 150,
168); residues from β2 involved in interactions with the peptide-binding
domain are colored blue (β123, 149, 151–153); and residues involved
in interactions between the α2 and β2 domains are colored magenta
(α92–94, 96, 106, 135, 146, 148, 150, β102, 118, 120, 148–152,
156). (b) Top view of the peptide-binding domain. The α-chain helical
region is shown at the top as a Cα trace with contact loops from the
lower domains indicated. Cα atoms are only shown for contact
residues, except for Trpβ153. Residue coloring is as in (a). (c)
Sequences of class II β2 and corresponding class I α3 domains, with
sequence identity (24% overall) indicated by vertical bars. Residues in
contact with the peptide-binding domain are indicated by asterisks, and
conserved immunoglobulin residues are indicated by the letter i. The
position labeled x corresponds to tryptophan in all class II proteins and
to glycine, or occasionally arginine, in class I proteins. 
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against the edge and loops of the four-stranded β sheet
from the α2 domain. This interaction buries 1200 Å2 of
molecular surface area, that would be accessible to solvent
for the free domains, and consists of a hydrophobic patch
formed by α2 residues from strand D and loops BC and
DE (Figure 5; red), which contacts hydrophobic
sidechains projecting from the underside of the peptide-
binding site. Several residues surrounding this hydro-
phobic patch form reciprocal polar sidechain–mainchain
interactions. The other contact area between the peptide-
binding domain and Ig-like domains (750 Å2) is formed by
the BC and DE loops at the top of the β2 domain
(Figure 5; blue), which project into a hydrophobic pocket
underneath the left-hand side of the peptide-binding
domain. This interaction is dominated by Trpβ153 which
extends from the β2 DE loop to interact with several α1
and β1 residues underneath the left-hand side of the
peptide-binding domain (Figure 5b), near pocket 1 (see
below). Tyrβ123 from the BC loop also projects up to
contact the peptide-binding domain. Finally, an additional
interaction (450 Å2) is formed between the two lower
domains α2 and β2 (Figure 2a; magenta), which pack at an
~100° angle. This interaction comprises mostly polar
residues sandwiched between the four-stranded β sheets
of each domain. 
The domain structure and interdomain interactions of
class II MHC proteins are very similar to those of class I
MHC proteins, but the class II β2 domain is oriented ~15°
away from the peptide-binding site relative to the corre-
sponding class I α3 domain [9]. The class II β2 and class I
α3 loop regions that contact the peptide-binding domain
are highly conserved, with the sequences Phe-Tyr-Pro
(BC loop) and Gly-Asp-x-Thr-Phe-Gln (DE loop) invari-
ant in all mouse and human class I and class II MHC pro-
teins (Figure 2c). In class II sequences the residue ‘x’ is
Trpβ153, which forms the principal β2 peptide-binding
domain contact described above. In class I sequences the
residue x is usually glycine. (In some sequences arginine
is found at this position, but the arginine sidechain has
been shown to project away from the upper domain [30].)
The presence of tryptophan or glycine at the top of the
class I α3 or class II β2 loops may be responsible for the
different orientation of these domains in class I and class
II MHC proteins. The orientation of these domains allows
formation of the class II crystallographic dimer of dimers
[9,13], aligns the peptide-binding site relative to the mem-
brane for interaction with the T-cell receptor, and controls
the accessibility of the binding sites for the T-cell co-
receptor CD8 [31,32] and CD4 [33] molecules on the β2
domain CD loop (Figure 5a).
Biological implications 
Class II major histocompatibility complex (MHC) mol-
ecules are type I transmembrane glycoproteins that bind
a large variety of peptides in intracellular endosomal
compartments and bring them to the cell surface for
inspection by receptors on T cells. Along with the
related class I MHC proteins, which generally bind pep-
tides that are produced in the cytoplasm and transported
to the endoplasmic reticulum, they provide T cells with a
sample of peptides derived from the endogenous and
exogenous proteins to which the cell has been exposed.
Peptide selection by class II MHC proteins can be char-
acterized by ‘motifs’ consisting of sidechain preferences
at particular positions within the peptide. Motifs have
been characterized for many allelic variants of class II
MHC proteins [7], and the three structures that are
available for complexes of class II MHC proteins with
single peptides have generally shown significant
MHC–peptide interaction at positions described in the
corresponding motifs [10–12]. Despite these studies,
however, the relationship of the observed binding prefer-
ences to the structure of the binding site is not yet under-
stood in detail, particularly by comparison with the
understanding of peptide binding by class I MHC pro-
teins [13]. For example, it is not possible to predict the
effect on the binding motif of MHC polymorphisms
observed among human class II MHC proteins. This
ability would be important in understanding the linkage
between the MHC genotype and certain autoimmune
diseases [34], and in predicting the antigenicity of poten-
tial therapeutic agents. 
In an effort to understand the structural basis for the
observed peptide specificity of HLA-DR1, a common
human class II MHC protein, and to determine the
extent of conformational variability allowed for bound
peptides, we have determined the three-dimensional
structure of HLA-DR1 in complex with a tight binding
endogenous peptide A2(103–117). The structure reveals
several peptide–MHC interactions that appear to be
important in determining the binding motif. In addition,
the relatively high resolution of the structure (2.45 Å)
allowed us to locate several water molecules in subsites
within the peptide-binding cleft. Variable binding of
such water molecules would appear to facilitate the
tight binding of different peptide sidechains in some of
the peptide-binding pockets. Comparison of the struc-
ture of the HLA-DR1–A2 peptide complex with that
previously determined for HLA-DR1 in complex with
a different peptide [10] shows that completely different
peptide sequences can adopt essentially the same
bound conformation, with little or no adjustment of the
MHC protein residues. 
The HLA-DR1–A2 peptide structure provides insight
into interactions of class II MHC proteins with other
physiological effectors. T cell receptor proteins bind
across the MHC peptide-binding site, contacting exposed
regions of the bound peptide and the adjacent MHC α-
helical regions [35]. Although the conformation of
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peptides bound to HLA-DR1 [8] and other class II
MHC proteins [11,12] is relatively stereotyped, the pre-
diction of important T-cell receptor–peptide contacts at a
physiologically significant level of detail may be difficult.
For example, alteration of wholly buried residues is
known to alter peptide recognition by particular T-cell
clones [36–38]. The peptide mainchain rearrangement
observed above one of the peptide-binding pockets,
pocket 1, as HLA-DR1 accommodates tryptophan of the
A2 peptide or tyrosine of the HA peptide appears to be
such a case, as T-cell clones have been isolated that dis-
tinguish tyrosine from tryptophan at this position (in the
context of another peptide bound to HLA-DR1) [39].
This rearrangement involves motions of only a few
atoms over distances of less than 1 Å, and highlights the
potential selectivity of the T-cell receptor–MHC inter-
action. Regions of the bound peptide outside the ‘core’
region could also influence T-cell receptor recognition if
they fold back onto the MHC helical regions, as observed
for the N terminus of the A2 peptide. A bent or kinked
conformation for the bound peptide could explain the
effect of C-terminal flanking tryptophan residues on T-
cell recognition of a peptide bound to the murine MHC
protein I-Ak [40]. It is possible that the bound peptide
could also interfere with other proteins involved in T-cell
recognition, as previously observed for the staphylococ-
cal toxin responsible for toxic shock syndrome [15]. In
the HLA-DR1–A2 peptide complex, two of the peptide
residues (an aspartate and an arginine residue) partially
block access to Hisβ81 and might be expected to interfere
with binding of the ‘superantigen’ staphylococcal entero-
toxin A (SEA), which is believed to bind to HLA-DR1
through coordination of Hisβ81 by a toxin-bond zinc ion
[41–43]. Finally, interdomain motions mediated by
residues at the domain interfaces may be important in
orienting the peptide-binding site relative to the cell mem-
brane for interaction with receptors on other cells.
Materials and methods
Production of the HLA-DR1–A2 peptide complex
HLA-DR1 was produced in baculovirus-infected Sf9 insect cells as
soluble empty αβ heterodimers as described [44], except that both
DRA*0101 and DRB1*0101 genes were carried on a single dual-pro-
moter recombinant baculovirus. This system provided two- to fourfold
increased HLA-DR1 expression levels and more consistent infection
than the two-virus system. Regions corresponding to the entire extra-
cellular domains were expressed (amino acid residues α1–192,
β1–198). To construct the dual-promoter vector, the EcoRV-KpnI frag-
ment containing the polyhedrin promoter and DRA*0101 gene was
excised from pACDRA [44], the KpnI 3′, overhang was filled in using
Klenow fragment, and the resultant blunt-ended DNA was ligated into
EcoRV-linearized pACDRB1 [44] to produce the final plasmid which
carries two polyhedrin promoters in the same orientation. The dual-pro-
moter plasmid was used to produce high-titer viral stocks by homolo-
gous recombination, as previously described. Soluble HLA-DR1 was
isolated by immunoaffinity chromatography from serum-free medium
used to grow baculovirus-infected Sf9 insect cells as described [44].
The peptide A2(103–117) VGSDWRFLRGYHQYA is a predominant
self-peptide bound to HLA-DR1 isolated from a B lymphoid cell line,
with longer and shorter versions of the same sequence observed at
lower abundance [2]. The A2 peptide was synthesized using 9-fluo-
renylmethyl carbonyl (FMOC) chemistry, purified by reverse-phase high
pressure liquid chromatography (HPLC), and characterized by fast-
atom bombardment (FAB) mass spectrometry to verify complete
deprotection and lack of unexpected modifications. Purified HLA-DR1
was incubated with a fivefold molar excess of A2 peptide at 37°C, pH
7.0, and the resultant complex was purified by gel filtration. 
Crystallization and data collection
Crystals of the HLA-DR1–A2 complex grew as needles from 10 mg/ml
protein, 15% PEG 4000, 100 mM glycine, pH 3.5, at room temperature
over approximately one week. A single crystal (40 µm × 40 µm × 300 µm)
was transferred to 25% w/w glycerol in the crystallization solution by
sequential incubation with increasing glycerol concentration over the
course of 30 min. The crystal was mounted in a nylon fiber loop, rapidly
cooled to –175°C and maintained at this temperature with a stream of
cold N2 gas. Diffraction data were collected using synchrotron radiation
at the MacCHESS facility F1 beamline (λ = 0.908 Å) as a series of 1°
oscillation photographs on storage phosphor image plates. Unit cell
dimensions were a = 134.51, b = 134.32, c = 131.23, α = γ = 90°,
β = 104.82°. Diffraction intensities were integrated and scaled using
Denzo and Scalepack (W Minor and Z Otwinoski, unpublished data)
(Table 2). The space group was found to be C2 by comparison of the
intensity of reflections related by potential symmetry elements, with four
HLA-DR1 αβ heterodimers per asymmetric unit. An overall isotropic B
factor was estimated to be 37 Å from a Wilson plot, with no evidence of
B-factor anisotropy. Data collection statistics are given in Table 2.
Molecular replacement
Initial phases were determined by molecular replacement using AMoRe
[45], with a 2.75 Å structure of HLA-DR1 complexed with the HA
peptide PKYVKQNTLKLAT [10] as search model. This model comprised
the noncrystallographic (αβ)2 dimer of heterodimers and included
residues 5–180 of 192 residues in the α chain and residues 5–190 of
198 residues in the β chain. The peptide was omitted from the search
model. Rotation search using 8 to 4 Å data and the (αβ)2 dimer of het-
erodimers revealed four peaks of greater than 11.8σ (standard deviation
above the mean rotation function) with no other peaks above 8.9σ, corre-
sponding to two unique solutions each twofold degenerate about the
(αβ)2 dimer axis. The presence of (αβ)2 dimers was confirmed by repeat-
ing the rotation search using a single αβ heterodimer, which resulted in
four corresponding unique solutions of slightly weaker intensity
(8.4–9.6σ). Similar results were obtained using other resolution limits.
Translation search in the xz plane with one rotation search solution
revealed a single peak of 17σ. This molecule was fixed and a three-
dimensional search was performed using the other rotation search solu-
tion, providing a single 37σ peak. After rigid-body refinement treating
each heterodimer as a rigid unit the R factor was 0.336 and correlation
coefficient 0.664, for all data 8–4 Å. The two (αβ)2 heterodimers in the
asymmetric unit are related by an 89° rotation, similar to the crystallo-
graphic fourfold screw axis relating (αβ)2 heterodimers in the P43212
space group observed for the HLA-DR1–HA structure. The αβ het-
erodimers within each (αβ)2 are related by an approximate twofold rota-
tion axis, with slightly different transformations relating the
α1/β1/peptide, α2, and β2 domains (176–180°), as has been observed
for other DR crystal structures [9–11]. A rotation search with a dimer of
heterodimers constructed using strict twofold symmetry gave a weaker
solution, confirming the departure from strict twofold symmetry. Electron-
density maps calculated omitting individual subunits revealed clear
density for the omitted regions. An omit map showing the peptide region
and calculated using the initial molecular replacement model is pre-
sented in Figure 1.
Noncrystallographic averaging, model building and refinement
Iterative real space fourfold noncrystallographic averaging was used to
improve the molecular replacement phases and to extend them from
3.0 Å to 2.45 Å. Separate molecular envelopes were generated for the
peptide-binding domain (α1β1) and for each of the immunoglobulin
domains (α2 and β2) using MAMA [46] and manual inspection of omit
maps. Fourfold averaging of electron density was performed using
RAVE [47], with the improved phases used to calculate new maps until
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convergence. A model for the bound peptide was built and the initial
DR1 model was adjusted using averaged electron-density maps that
were calculated by omitting coordinates for the region under considera-
tion. The rebuilt model was refined using X-PLOR [48] with rigid body,
simulated annealing, positional, and restrained B-factor refinement
steps. At this point the R factor for the model was 0.294 for all reflec-
tions 6–2.45 Å with F > 2σF, and the free R factor, calculated using
reflections not included in any refinement steps and comprising 10% of
the total reflections, was 0.326. Eight cycles of rebuilding and refine-
ment brought the R factor to 0.217 and the free R factor to 0.288. After
cycle three the phase averaging was discontinued although noncrystal-
lographic symmetry (NCS) restraints relating the four molecules in the
asymmetric unit were continued for all refinement steps. Atoms involved
in crystal contacts were not included in the NCS restraints. The NCS
restraint weights were determined by examination of the free R factor,
with optimum restraints relating the two (αβ)2 units tighter than those
relating the two αβ molecules within each (αβ)2 dimer. Water molecules
were added based on peaks in Fobs– Fcalc difference maps identified
using the CCP4 suite of programs [49] and ARP [50], and on hydro-
gen-bonding distance and geometry criteria. Refinement steps per-
formed using REFMAC [49] were included in cycles seven, eight and
nine. The final model includes coordinates for DR1 residues α3–α181
(of 192 residues), β4–β190 (of 198 residues), peptide residues A2
104–117 (of 103–118), and 152 water molecules (Table 2). Weak
electron density was observed for the expected three carbohydrate moi-
eties of HLA-DR1 but did not permit determination of an atomic model.
The loop regions β106–111 and β166–168 exhibited weak electron
density and large B factors, particularly in molecule three, and were
modeled without sidechain occupancy in molecules one, two and four
and were not included at all in molecule three. Residue Glnβ64 was dis-
ordered in all molecules and was not included in the model. These
regions were also observed to be disordered in other class II structures. 
Analysis
Model geometry was examined using Procheck [51] and found to meet
or exceed criteria determined for structures of similar resolution. Only one
residue, Asnβ33, fell outside allowed regions of a Ramachandran plot.
The φ angle of this residue is unusual, allowing a turn to be formed with
hydrogen bonds between the β33 sidechain, β8 backbone amide, and
α80 backbone carbonyl. Rms deviation from ideal geometry is 0.016 Å
for bond lengths, 2.53° for bond angles, and 26.0° for dihedral angles.
Average coordinate error was estimated to be 0.3 Å by Luzzati analysis
[52] and 0.27 Å by SIGMAA analysis [53]. Rms deviations between
pairs of noncrystallographically-related molecules is 0.9 Å (molecules
one–three or two–four) or 1.8 Å (molecules one–two or three–four), but
is considerably smaller, 0.3–0.5 Å, if the α1/β1/peptide, α2, and β2
domains are considered separately. The latter values are commensurate
with the expected coordinate error. Standard deviations of symmetry-
related torsion angles φ, ϕ, χ1 and χ2 are 6–7°. Average B factors are
40 Å2 (mainchain) and 41 Å2 (sidechain) for the MHC protein, 42 Å2 for
solvent molecules, and 51 Å2 (mainchain) and 54 Å2 (sidechain) for the
peptide. Average RS-fit [54] values were 0.82 (mainchain) and 0.78
(sidechain) for both the MHC protein and the peptide, and 0.69 for the
solvent. B factors and RS-fit values were not significantly different among
the four molecules in the asymmetric unit. The programs ACCESS [55],
and MS [17] were used to analyze solvent accessibility and molecular
surfaces, LSQMAN [56] and LSQKAB [57] to determine relationships
among the NCS-related molecules, and MOLSCRIPT [58], RIBBONS
[59], RASTER 3D [60], O [54], and GRASP [61] to display the struc-
ture. To evaluate the significance of differences observed between the
HLA-DR1–A2 complex determined here and other class II MHC crystal
structures, we considered the rms deviations between NCS-related
atoms not involved in crystal contacts and the expected coordinate error,
and used these values in considering differences with other structures. 
Accession numbers
Coordinates and structure-factor amplitudes have been deposited in
the Brookhaven Protein Data Bank with accession code 1AQD.
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